Vertex announces publication in new england journal of medicine of results from phase 2 study of inaxaplin (vx-147)

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced publication in the new england journal of medicine (nejm) of results from preclinical studies and a phase 2 study evaluating the efficacy and safety of inaxaplin (vx-147) on top of standard-of-care in people with focal segmental glomerulosclerosis (fsgs) and two apol1 variants, a severe, rapidly progressive form of chronic kidney disease also known as apol1-mediated kidney disease (amkd).
VRTX Ratings Summary
VRTX Quant Ranking